Home Page | Zirabev™ (bevacizumab-bvzr) HCP Website | Safety Info
Pfizer is building onto the clinical experience of bevacizumab ZIRABEV is a biosimilar* to Avastin® (bevacizumab) that was approved by the FDA based on the totality of evidence 1,2. ZIRABEV offers the potential to help address treatment costs and shows no clinically meaningful differences to Avastin 1-3. Approved for the eligible indications of Avastin 1. See dosing & …
DailyMed - ZIRABEV- Bevacizumab-bvzr Injection, Solution
ZIRABEV (bevacizumab-bvzr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to pale brown solution in a single-dose vial for intravenous use. ZIRABEV contains bevacizumab-bvzr at a concentration of 25 mg/mL in either 100 mg/4 mL or 400 mg/16 mL single-dose vials. Each mL of solution contains 25 mg bevacizumab-bvzr, edetate disodium …
Zirabev ( Bevacizumab
HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------- …
DailyMed - ZIRABEV- bevacizumab-bvzr injection, solution
Zirabev | European Medicines Agency
Zirabev | European Medicines Agency
Pfizer Receives U.S. FDA Approval For Its Oncology Biosimilar, …
Pfizer Receives U.S. FDA Approval for Its Oncology
Zirabev - INN- Bevacizumab - Europa
The active substance in Zirabev, bevacizumab, is a monoclonal antibody ( a type of protein) that has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and encourages the growth of new blood vessels. By attaching t o VEGF, Zirabev stops its effect. As a result, the cancer cannot develop its own blood supply and cancer cells …
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ZIRABEV (bevacizumab-bvzr) is biosimilar* to AVASTIN (bevacizumab).----- INDICATIONS AND USAGE----- ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the . treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in …
SAFETY DATA SHEET - Pfizer
11/12/2018 · The active substance in Zirabev, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and encourages the growth of new blood vessels. By attaching to VEGF, Zirabev stops its effect. As a result, the cancer cannot develop its own blood supply …
Images Of Zirabev Bevacizumab
About ZIRABEV (bevacizumab-bvzr) ZIRABEV is a mAb biosimilar of the reference product, Avastin, which works by inhibiting the formation of new blood cells (angiogenesis) by specifically recognizing and binding to vascular endothelial growth factor (VEGF) protein. As part of the REFLECTIONS clinical trial program, ZIRABEV has been studied in nearly 400 patients to …